Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Luca Licata"'
Autor:
Giulia Notini, Matteo Maria Naldini, Lorenzo Sica, Giulia Viale, Alessia Rognone, Stefania Zambelli, Patrizia Zucchinelli, Marta Piras, Carlo Bosi, Marco Mariani, Daniela Aldrighetti, Giampaolo Bianchini, Luca Licata
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundNausea and vomiting are common side effects of Trastuzumab Deruxtecan (T-DXd), but guidelines for optimal management were not initially available. This retrospective single-center study aimed at evaluating the efficacy of two antiemetic reg
Externí odkaz:
https://doaj.org/article/ca65e1973791437daeee94e6e27e63a0
Autor:
Luca Licata, Giulia Viale, Mario Giuliano, Giuseppe Curigliano, Mariana Chavez-MacGregor, Julia Foldi, Oluchi Oke, Joseph Collins, Lucia Del Mastro, Fabio Puglisi, Filippo Montemurro, Claudio Vernieri, Lorenzo Gerratana, Sara Giordano, Alessia Rognone, Lorenzo Sica, Oreste Davide Gentilini, Stefano Cascinu, Lajos Pusztai, Antonio Giordano, Carmen Criscitiello, Giampaolo Bianchini
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-7 (2023)
Abstract Adjuvant chemotherapy recommendations for ER+/HER2− early-stage breast cancers (eBC) involve integrating prognostic and predictive information which rely on physician judgment; this can lead to discordant recommendations. In this study we
Externí odkaz:
https://doaj.org/article/71af898d79424e0aa99424fea6092b45
Autor:
Luca Licata, Marco Mariani, Federico Rossari, Giulia Viale, Giulia Notini, Matteo Maria Naldini, Carlo Bosi, Marta Piras, Matteo Dugo, Giampaolo Bianchini
Publikováno v:
Breast, Vol 69, Iss , Pp 330-341 (2023)
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy and now represent the mainstay of treatment for many tumor types, including triple-negative breast cancer and two agnostic registrations. However, despite impressive durable respo
Externí odkaz:
https://doaj.org/article/8a3ed9d7d5134608972f9456bef24617
Autor:
Luca Licata, Deborah Cosentini, Rita De Sanctis, Monica Iorfida, Elena Rota Caremoli, Andrea Vingiani, Edda Lucia Simoncini, Giancarlo Pruneri, Elisabetta Munzone, Giampaolo Bianchini, Alberto Zambelli, Carlo Tondini
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
The increasing understanding of breast cancer biology has provided the basis for the development of multigene signatures aimed to improve the capability of clinicians to assess patients’ prognostication and risk stratification. Incorporating these
Externí odkaz:
https://doaj.org/article/6a67d1afaa084dd89c84e592f33d434c
Autor:
Raffaella Palumbo, Federico Sottotetti, Erica Quaquarini, Anna Gambaro, Antonella Ferzi, Barbara Tagliaferri, Cristina Teragni, Luca Licata, Francesco Serra, Pietro Lapidari, Antonio Bernardo
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 11 (2019)
Background: Fulvestrant 500 mg (F500) is the most active endocrine single agent in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (MBC). Few data are available regarding the effectiveness of the drug in a real-world setting. P
Externí odkaz:
https://doaj.org/article/9cfbbf8d30714d2d8bb8d327bcd237e6
Autor:
Giulia Viale, Veronica Zuber, Patrizia Zucchinelli, Giovanna Petrella, Nadia Di Muzio, Luca Licata, Oreste Gentilini, Pietro Panizza, Maria Grazia Rodighiero, Daniela Aldrighetti, Lorenzo Sica, Rosa Di Micco, Giampaolo Bianchini, Alessia Rognone, Stefania Zambelli, M. Pasetti, Stefano Cascinu, Isabella Sassi
Publikováno v:
The Oncologist
Northern Italy has been one of the European regions reporting the highest number of COVID‐19 cases and deaths. The pandemic spread has challenged the National Health System, requiring reallocation of most of the available health care resources to t
Autor:
Lucia Del Mastro, Antonio Frassoldati, Giancarlo Bisagni, Mauro Mansutti, Stefania Zambelli, Marco Colleoni, Claudio Zamagni, Luca Licata, Pinuccia Valagussa, Giuseppe Viale, Chanel Smart, Giampaolo Bianchini, Luca Gianni
Publikováno v:
Cancer Research. 80:P4-14
Background We assessed TILs before and during treatment in patients with ER+/HER2+ breast cancer (BC) enrolled in the NA-PHER2 study, and evaluated the association between TILs and their modulation over treatment with likelihood of achieving a pCR. M
Publikováno v:
1st Croatian Conference on Earthquake Engineering.
Autor:
Cristina Teragni, Luca Licata, Raffaella Palumbo, Erica Quaquarini, Barbara Tagliaferri, Antonio Bernardo, Emma Pozzi, Federico Sottotetti
Publikováno v:
Oncology Research and Treatment. 41:8-13
Introduction: Vinflunine is a microtubule inhibitor approved in Europe as second-line treatment of advanced transitional cell cancer of the urothelium (TCCU). The inability to continue with a first-line platinum-based regimen beyond 6 cycles suggeste
Autor:
Maurizio Callari, Giancarlo Bisagni, Antonio Frassoldati, M. Dugo, Luca Licata, Claudio Zamagni, Barbara Galbardi, Lucia Del Mastro, M. Mansutti, Stefania Zambelli, Alberta Locatelli, Luca Gianni, Marco Colleoni, Pinuccia Valagussa, Giuseppe Viale, Chanel Smart, Balazs Gyorffy, Giampaolo Bianchini, Lucia Viganò, Maria Olivia Biasi
Publikováno v:
Journal of Clinical Oncology. 39:555-555
555 Background: In the NA-PHER2 study we assessed the association between biological pathways with pathological complete response (pCR) and Ki67 down-regulation Methods: Patients with centrally confirmed ER+ ( > 10%) HER2+ breast cancer (BC) were tre